A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies
Purpose
The purpose of this study is to evaluate the safety and preliminary clinical activity of treatment combinations with and without chemotherapy in participants with locally advanced unresectable or metastatic gastric, GEJ, and esophageal adenocarcinoma. Chemotherapy will consist of FOLFOX (oxaliplatin, leucovorin, fluorouracil).
Condition
- Gastrointestinal Tract Malignancies
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Genders
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Participants with histologically confirmed diagnosis of locally advanced unresectable or metastatic gastric, GEJ, or esophageal adenocarcinoma with life expectancy ≥3 months as assessed by the Investigator - Eastern cooperative oncology group (ECOG) Performance Score of 0-1 - At least one measurable target lesion per RECIST v1.1. - Adequate organ and marrow function - Able to provide an archival tumor sample that is representative of the cancer under investigation and suitable for central PD-L1 testing
Exclusion Criteria
- Participants with underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of investigational products hazardous - Only for Cohort A: Known Human Epidermal Growth Factor Receptor 2 (HER-2) positive tumor - Known untreated, symptomatic, or actively progressing central nervous system (brain) metastases. Participants with leptomeningeal metastases are excluded from enrollment. - Discontinued use of prior immune checkpoint therapy due to immune related adverse events; received prior treatment with an anti-TIGIT monoclonal antibody. - History of trauma or major surgery within 28 days prior to enrollment. Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Design
- Phase
- Phase 2
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental A1: First Line - Treatment Naïve Participants |
Domvanalimab and zimberelimab once every 4 weeks (Q4W) in addition to FOLFOX chemotherapy by intravenous (IV) infusion once every 2 weeks (Q2W) |
|
|
Experimental A2: First Line - Treatment Naïve Participants |
Zimberelimab Q4W in addition to chemotherapy with FOLFOX administered by IV infusion Q2W |
|
|
Experimental A3 First Line - Treatment Naïve Participants |
Non-randomized A3 safety run-in cohort: Domvanalimab and zimberelimab co-administered Q4W via IV infusion over 60 minutes in addition to FOLFOX chemotherapy via IV infusion Q2W. After completion of A3 safety run-in cohort, participants are randomized to the A3 arm. Domvanalimab and zimberelimab co-administered Q4W via IV infusion over 30 minutes, in addition to FOLFOX chemotherapy via IV infusion Q2W |
|
|
Experimental A4 First Line - Treatment Naïve Participants |
Zimberelimab administered Q4W via IV infusion over 30 minutes, in addition to FOLFOX chemotherapy via IV infusion Q2W |
|
|
Experimental B1: Second Line or greater Checkpoint Inhibitor Naïve Participants |
Domvanalimab and zimberelimab administered once every three weeks (Q3W) by IV infusion |
|
|
Experimental B2: Second Line or greater Checkpoint Inhibitor Naïve Participants |
Quemliclustat Q2W and zimberelimab Q4W administered by IV infusion |
|
|
Experimental Cohort C1: Second Line or greater - Checkpoint Inhibitor Experienced Participants |
Domvanalimab and zimberelimab Q3W administered by IV infusion |
|
Recruiting Locations
Massachusetts General Hospital
Boston, Massachusetts 02109
Boston, Massachusetts 02109
More Details
- Status
- Recruiting
- Sponsor
- Arcus Biosciences, Inc.